SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Rein Therapeutics Announces Preliminary Blinded Phase 2 RENEW Data Showing Encouraging Lung Function Trends in Patients with Idiopathic Pulm

33% of evaluable patients demonstrated improvement over baseline in forced vital capacity (FVC) at W

RNTX

Related stories